Polymyalgia rheumatica is the second most frequent inflammatory rheumatic disease in people aged over 50 years, after rheumatoid arthritis. It is characterized by pain and morning stiffness in the region of the shoulders, hip girdle and neck. It can be associated with giant cell arteritis (CGA). Treatment with glucocorticoids is indispensable. The duration of treatment varies and often exceeds 1 year. The additive administration of methotrexate is an option for saving glucocorticoids. The biologicals tocilizumab or secukinumab are very promising alternatives. The course of treatment should be closely monitored for inflammation parameters, glucocorticoid side effects, pain, visual acuity, depression, activities of daily living and especially related to functions of the upper extremities. The geriatric assessment plays an important role in the management of this condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00393-024-01484-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Isolated inflammatory involvement of the occipital artery in giant cell arteritis and polymyalgia rheumatica: findings from a retrospective analysis and the critical role of MRI in diagnosis.
Rheumatol Int
January 2025
Department of Diagnostic and Interventional Radiology, University Hospital Wuerzburg, Oberduerrbacher Strasse 6, 97080, Wuerzburg, Germany.
Background: Diagnosis of Giant Cell Arteritis (GCA) and Polymyalgia rheumatica (PMR) may be challenging as many patients present with non-specific symptoms. Superficial cranial arteries are predilection sites of inflammatory affection. Ultrasound is typically the diagnostic tool of first choice supplementary to clinical and laboratory examination.
View Article and Find Full Text PDFThe Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.
Curr Neurol Neurosci Rep
December 2024
Anschutz Medical Campus, Strauss Health Sciences Library, University of Colorado, Aurora, Colorado, USA.
Purpose Of Review: To describe recent research relevant to factors which predispose to giant cell arteritis (GCA) and those which trigger its manifestation, with particular emphasis on the more recent and controversial associations (COVID-19, vaccination, novel medications) which have changed the medical landscape and perhaps GCA prevalence.
Recent Findings: GCA remains more prevalent in Caucasians but nevertheless affects other racial groups. Certain HLA haplotypes (i.
Comprehensive analysis of rheumatic diseases, comorbidities, and mortality in geriatric population: Real-world data of 515 patients in a single rheumatology clinic.
Medicine (Baltimore)
November 2024
Department of Medicine, Rheumatology, School of Medicine, Halic University, Istanbul, Turkey.
Article Synopsis
- Geriatric patients (aged 65 and older) present different patterns of rheumatic diseases compared to younger patients, with significantly higher rates of rheumatoid arthritis, polymyalgia rheumatica, crystal arthritis, and osteoarthritis.
- They also experience more comorbidities such as hypertension, diabetes, and osteoporosis, indicating a greater burden of chronic health issues.
- Treatment approaches vary, with geriatric patients using more corticosteroids and traditional synthetic treatments but fewer biological treatments, and they have higher mortality rates linked to conditions like cancer and heart disease.
Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies.
BMC Genomics
November 2024
Precision Medicine & Computational Biology, Sanofi, Cambridge, MA, USA.
Background: Therapeutic targets supported by genetic evidence from genome-wide association studies (GWAS) show higher probability of success in clinical trials. GWAS is a powerful approach to identify links between genetic variants and phenotypic variation; however, identifying the genes driving associations identified in GWAS remains challenging. Integration of molecular quantitative trait loci (molQTL) such as expression QTL (eQTL) using mendelian randomization (MR) and colocalization analyses can help with the identification of causal genes.
View Article and Find Full Text PDFPsyllium husk (Metamucil®) induced perennial asthma: A case report.
Respir Med Case Rep
September 2024
Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Canada.
Article Synopsis
- A 44-year-old nurse developed asthma symptoms after inhaling Metamucil®, a fiber supplement, indicating that even a single exposure can trigger respiratory issues in sensitive individuals.!* -
- Despite no further exposure, she struggled with asthma management for 30 years, leading to reliance on chronic prednisone and experiencing exacerbations and chronic cough.!* -
- The case highlights the potential severe reactions to psyllium in Metamucil® and stresses the importance of caution for people without a prior asthma history.!*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!